(Received for publication November 5, 1998) Mulundocandin (MCN)is an antifungal lipopeptide which belongs to the echinocandin class of antimycotic agents. MCNexhibited good in vitro activity against Candida albicans and C. glabrata isolates with MIC ranges of0.5~4.0 /ig/ml and 2.0~4.0^g/ml, respectively. MCNalso exhibited some activity against C. tropicalis isolates (MIC range 1.0~8.0 jug/ml). However, MCNwas poorly active against other non-albicans isolates and was inactive against Cryptococcus neoformans, Aspergillus species and Trichophyton. MCNappeared to exert its antifungal activity through preferential inhibition of germ tube formation (MIC-HY 0,015~0.03/ig/ml) and was typically less active on the yeast form (MIC 0.5~4.0^g/ml). In kill-curve experiments 99.9 % reductions in cell viability were observed following 8 hours exposure to MCNat 4 x MICand 8 x MIC and after 5 hours exposure to 16xMIC.
The emergence of azole-resistant isolates ofpathogenic yeasts in the clinic, particularly those resistant to fluconazole, and the failure of treatment of systemic mycoses in HIV-positive and full blown AIDSpatients, are growing concerns among infectious disease specialists1>2) There is, therefore, an urgent need for new antifungal agents which demonstrate potent, broad spectrum and efficacious activities in the therapy of serious fungal infections, and the potential to overcome problems associated with drug resistance. One avenue of research that has lead to the discovery and development of newantifungal agents is that of the The MICof each isolate to the antifungal agents was assessed as follows. Susceptibility testing was performed in 96-well tissue culture plates as described in the M27-A procedure for the susceptibility testing of yeasts. The MIC for yeasts was read visually as described in the NCCLSM27-A document7*. For MCN, MICs were read in the same way as described for amphotericin B7). MICs of filamentous fungi and dermatophytes were performed as above except that an inoculum of 1 x 105 CFU/mlwas used and the MICsread visually in the same way as for the yeasts after 72 hours incubation at 35°C.
MinimumFungicidal Concentration (MFC) Deter- 
Effect of Inoculum Size on the MIC
The effect of inoculum size on the activities of the antifungal agents against C. albicans was assessed. MICs were performed as described above, using C. albicans ATCC10231, with the exception that inocula of 102~6 cfu/ml were used. performed at least three times.
Time Kill Curves
The killing activities of MCNand AMBagainst actively metabolizing yeast cells were determined in RPMI-1640 medium in shaking flasks at 35°C. In brief, an overnight culture of C. albicans ATCC10231 was prepared as previously described8) and inoculated at l x lO6 cfu/ml into 100ml of RPMI-1640 medium. MCNor AMBwere added to the log-phase cultures at 0.5xMIC, lxMIC, 2xMIC, 4xMIC, 8xMIC and 16xMICor0.5xMIC, 1 XMIC,2xMIC,4xMICand 8 x MIC, respectively. A separate group of cells were allowed to grow in the absence of antifungal agent (drug free control). Samples were taken for up to 24 hours and growth curves were established following plating of the samples on drug free SDAplates and enumeration of colony forming units.
Results
MICand MFCDeterminations MCNwas tested against a total of 66 yeast isolates.
MCNexhibited good activity against 18 C. albicans isolates with an MIC range of 0.5~4.0jUg/ml ( Table 1) . The compound also showed good activity against 12 C. glabrata isolates with an MIC range of 2.0~4.0 jUg/ml, and was also quite active against 5 C. tropicalis C. glabrata (12) C. krusei (10) C. parapsilosis (6) C. tropicalis ( (Table  1) . Furthermore, its activity against C. glabrata was comparable to that exhibited by AMB (Table 1) . MCNwas not active against the 6 C. neoformans isolates, though both AMB and FC were typically active and the azole agents showed good to variable activity (Table 1) . MCNwas typically not active against either the Aspergillus isolates or against Trichophyton isolates ( Table 2 ). The exception to these findings was that several of these isolates were susceptible to MCNat high concentrations (MIC 32 or >32jUg/ml) ( Table 2) . MCNexhibited a slightly lower fungicidal potential as compared with AMBagainst C. albicans and C. glabrata at 4~8 x MICand exerted fungicidal activity against C. tropicalis at 8~16 x MIC. By contrast, AMB was fungicidal against the different Candida species at 2~4x MIC(data not shown).
Activity Against the Morphogenetic Transformation
MCN was equally active against the morphogenetic transformation in C. albicans in both azole-susceptible and azole-resistant C. albicans isolates (Table  3) . Interestingly, MCN inhibited the transformation at sub-MIC values. For example, MCN inhibited the transformation at 0.01 5~0.03 /xg/ml and was more active than AMB (Table 3) . By contrast, the azoles and FC were poor inhibitors of the morphogenetic transformation in C. albicans (Table 3) . Comparisons of the effects of MCNby MIC and by inhibition of the morphogenetic transformation (MIC-HY) gave MIC/MIC-HY ratios for MCNof64-128 (Table 3) . By contrast, AMBgave ratios of 2.0-4.0 and the other agents gave ratios of < 0.02 (Table 3 ). The data, therefore, suggests that MCN preferentially inhibits growth of C. albicans by blocking germ tube formation and is less able to inhibit growth of the yeast by budding. The activity of each antifungal agent was assessed using MIC inocula of 102~106cfu/ml (see Materials and Methods). The bars represent the mean (4 C. albicans strains) MICfor each antifungal agent and are expressed as^g/ml.
Effects of Inoculum and Serum
Whentested against four C. albicans isolates, added as inocula of 102, 103, 104, 105 and 106, the activity of MCNwas slightly affected by inoculum size (Fig. 1) . For example, with inocula of 105 or 106 the activity ofMCN was reduced two-fold or four-fold, respectively, in comparison to the activity achieved with an inoculum of 103 (Fig. 1) . By contrast, AMBwas typically unaffected by inoculum size though the azoles and FC exhibited significantly reduced activities when using inocula of 106 cells/ml (Fig. 1) . MCNand AMBwere tested against four C. albicans isolates in the absence or presence of whole human serum (20~60%). In the presence of 20 %serum, the activity of MCNwas reduced four-fold and in the presence of40% serum two isolates gave MICs The values represent the range of MICsfor four C. albicans isolates.
Fig. 2. Killing activity ofMCN (A) and AMB (B).
The killing activities of AMBand MCNwere assessed at different concentrations as described in Materials and Methods. The data points represent the log10 CFU/ml. The limit of detection is represented by the dotted line. of 8.0^g/ml and two gave MICs of > 16^g/ml (Table   4 ). Furthermore, MCNwas inactive when tested in the presence of60% serum (Table 4) . By contrast, the activity of AMBwas not significantly affected by the addition of serum (Table 4) .
Killing Activity
The killing activity of MCNwas compared with the killing activity of AMB (Fig. 2) . MCN caused a > 99.9% reduction in cell viabilities following exposure of the cells to MCNfor 5 hours at 16xMICor after 8
hours at 4xMIC or 8xMIC ( Fig.  2A) . Some reductions in cell viability were observed after 5 hours in the presence of 2xMIC, however, MCN at this concentration was not effective in killing the population ( Fig. 2A) . By contrast, AMBcaused >99.9% reductions in cell viabilities following 1 hour exposure to 8 x MIC, 3 hours exposure to 4xMICand 5 hours exposure to 2xMIC (Fig. 2B) .
Discussion
MCNwas first isolated in the laboratories of Hoechst India Ltd.6) from the fermentation broth of A. sydowii and was described as an echinocandin-like molecule5'6). Membersof the echinocandin class of molecules tend to exhibit good activities against the majority of Candida species, typically lack activity against Cryptococcus and exhibit poor activities against filamentous and dermatophytic fungi5). The lack of activity against Cryptococcus shown here for MCNwas not surprising given that other membersof this class are also poorly active against this yeast5).
In terms of its biological properties in vitro, MCN appears to share several characteristics with those exhibited by other members of the lipopeptide class of antifungal agents3~5). For example, MCN exhibited good activities against C albicans, C. glabrata and C. tropicalis. However, MCNwas poorly active against other Candida s^., C. neoformans, filamentous fungi and dermatophytes. The activity of MCNwas also attractive in that its activity against both FLZ-susceptible and FLZ-resistant C. albicans strains was good and comparable to those exhibited by AMB. Furthermore, the compoundappeared to preferentially exert its action against C. albicans through inhibition of germ tube formation , an attribute which may be important in vivo, rather than by inhibition of growth through budding.
Moreover, MCNwas fungicidal at 4~8 x MIC and in kill curve experiments it exhibited a rapid 99.9% kill against C. albicans.
The lipopeptide class of new antifungal agents appears to be a promising class of new antifungal agents. Members of this class including MCN, LY-3033669) and MK-09911O) exhibit a high fungicidal potential and are clearly differentiated from other antifungal agents in their MAR. 1999 mechanism of action through inhibition of 1 ,3 jS-D-glucan synthesis. This class of molecules may prove to be useful in treating azole-resistant pathogenic yeasts.
